Why Some Cancer Trials Succeed — And Others Don’t -By Dr. Nonso Nwosu, Dr. Amin Yakubu, Dr. Enomfon-Nicole Ebose & Chisom Juanita Mefor

What Hematologic Research in Africa Must Get Right
We often talk about the need for more cancer research in Africa, more trials, more funding, more innovation, as though the primary gap is simply volume. But beneath that conversation sits a quieter and more fundamental question: what actually makes a clinical trial succeed? In hematologic conditions such as leukemia, lymphoma, and multiple myeloma, success is not guaranteed. New therapies enter trials every year with strong scientific rationale and early promise, yet a significant number do not make it through later phases or fail to meet their primary endpoints.

In hematologic malignancies such as leukemia, lymphoma, and multiple myeloma, success is not simply a function of scientific promise. Many therapies enter trials with strong rationale and early signals, yet fail in later phases or do not meet primary endpoints. These outcomes are not random. They reflect deeper structural realities: how patients are selected, how data is captured, and how systems support interpretation over time. Understanding this distinction is essential for regions like Africa, where the opportunity is not just to increase research activity but to build the conditions that allow research to generate meaningful, reproducible insight.

When Trials Fail: The Problem Is Rarely the Drug Alone
Failures in oncology trials are often attributed to biology. In reality, they are frequently driven by system-level weaknesses. Consider gemtuzumab ozogamicin, developed for acute myeloid leukemia. Early studies suggested promise, but larger trials revealed safety concerns and limited survival benefit. The drug was withdrawn, only to return years later with revised dosing and more precise patient selection. What changed was not the molecule; it was the understanding of context.

Across oncology, common causes of trial failure include poor patient accrual that limits statistical power, overly restrictive eligibility criteria, high dropout rates often tied to socioeconomic barriers, inconsistent or incomplete data capture, and lack of longitudinal follow-up. In many cases, trials do not fails but because the system is not designed to reveal where that value exists.

When Trials Succeed: Precision and Systems Working Together
Contrast this with imatinib in chronic myeloid leukemia. Its success was not solely due to its mechanism of action but to the ecosystem around it. Researchers identified a specific genetic driver in BCR-ABL, selected patients based on that biology, and tracked outcomes systematically over time. The result was transformative, not just a successful trial but a paradigm shift in disease management.

The lesson is clear: breakthrough therapies do not succeed in isolation. They succeed within systems that are precise, structured, and longitudinal.

That system determines how patients are identified, how data is standardized and captured, how outcomes are measured over time, and how clinical and molecular data are integrated. When these elements are weak, even promising therapies can appear ineffective. When they are strong, even modest signals can be translated into meaningful advances. This distinction is particularly important in hematologic malignancies, where outcomes are often shaped by subtype, molecular profile, and longitudinal response patterns.

The African Context: A Structural Challenge, Not a Scientific One
Across Nigeria and much of Africa, the challenge is not a lack of clinical need or scientific potential; it is fragmentation. Clinical records are often non-standardized or paper-based, data systems are not interoperable across institutions, long-term follow-up is inconsistent, and diagnostic capacity can be limited or delayed. As a result, even when research is conducted, it is difficult to generate datasets robust enough to guide clinical or scientific decision-making at scale.

At the same time, hematologic malignancies are common and under-characterized, trial participation remains low, skilled research personnel are limited but growing, and regulatory and operational complexity slows multi-site coordination. These are not permanent barriers. They are infrastructure gaps.

From Fragmentation to Systems: A Path Forward
Global experience offers a clear blueprint. Successful trials are built on defined patient populations, standardized clinical data collection, linked biospecimen and genomic data, longitudinal follow-up frameworks, and interoperable, analyzable datasets. These are not abstract ideals. They are design principles, and they can be built.

Building the Missing Infrastructure
This is the context in which the Claremont Amany Institute was established. CAI’s core premise is that advancing cancer research in Africa requires more than individual studies; it requires durable, integrated infrastructure. Its flagship initiative, the African Hematologic Cancer Biobank and Longitudinal Cohort Study, is designed to address the structural limitations that have historically constrained research output.

The model is deliberate: multi-site enrollment across tertiary hospitals in Nigeria, standardized clinical data collection using interoperable definitions, biospecimen collection and centralized biobanking, integration of genomic and molecular data, and structured longitudinal follow-up to capture outcomes over time. This approach creates something fundamentally different from isolated trials: a connected dataset where clinical trajectories, biological signals, and treatment responses can be understood together.

Why This Matters
The implications are significant. By linking biospecimens to structured clinical data, molecular findings can be interpreted in real-world context, patient subgroups can be defined with greater precision, treatment responses can be tracked longitudinally, and research becomes cumulative rather than episodic. This is the same principle that enabled therapies like imatinib to succeed, and that allowed previously failed therapies like gemtuzumab ozogamicin to be reintroduced with refined use.

A Shift in Perspective
For Africa, the question is not whether breakthrough therapies will emerge locally or globally. The question is whether the systems exist to identify, validate, and apply them effectively within African populations. This requires a shift: from isolated studies to integrated platforms, from fragmented data to standardized datasets, and from external dependency to local research leadership.

Conclusion: Success Is Designed
Across oncology, the difference between trials that succeed and those that fail is not unpredictable. It is structural. Success comes from clear patient selection, reliable data systems, longitudinal follow-up, and integrated clinical and biological insight. These are not optional components; they are the foundation.

For Africa, the opportunity is not simply to participate in global research but to build the infrastructure that defines it. Because what is not structured cannot scale. What is not standardized cannot be compared. And what is not measured cannot be improved.
The path forward is increasingly clear. The work now is to build the systems that make success not an exception, but an expectation.

Contributors:
Dr. Nonso Nwosu • Dr. Amin Yakubu • Dr. Enomfon-Nicole Ebose • Chisom Juanita Mefor